Denosumab after 8 years

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2015) Dennis M. Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Efficacy, effectiveness and side effects of medications used to prevent fractures

(2015) I. R. Reid   JOURNAL OF INTERNAL MEDICINE

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Michael Gnant et al.   LANCET

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

(2015) S. Papapoulos et al.   OSTEOPOROSIS INTERNATIONAL

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

(2015) S. Ferrari et al.   OSTEOPOROSIS INTERNATIONAL

Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?

(2014) Felicia Cosman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Risk of Atypical Femoral Fracture during and after Bisphosphonate Use

(2014) Jörg Schilcher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial

(2010) Ann V Schwartz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

(2010) Ian R Reid et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur

(2010) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE